PICALM and Alzheimer's Disease: An Update and Perspectives

Cells. 2022 Dec 10;11(24):3994. doi: 10.3390/cells11243994.

Abstract

Genome-wide association studies (GWAS) have identified the PICALM (Phosphatidylinositol binding clathrin-assembly protein) gene as the most significant genetic susceptibility locus after APOE and BIN1. PICALM is a clathrin-adaptor protein that plays a critical role in clathrin-mediated endocytosis and autophagy. Since the effects of genetic variants of PICALM as AD-susceptibility loci have been confirmed by independent genetic studies in several distinct cohorts, there has been a number of in vitro and in vivo studies attempting to elucidate the underlying mechanism by which PICALM modulates AD risk. While differential modulation of APP processing and Aβ transcytosis by PICALM has been reported, significant effects of PICALM modulation of tau pathology progression have also been evidenced in Alzheimer's disease models. In this review, we summarize the current knowledge about PICALM, its physiological functions, genetic variants, post-translational modifications and relevance to AD pathogenesis.

Keywords: Alzheimer’s disease; GWAS; PICALM; amyloid β; microglia; neurofibrillary tangles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / genetics
  • Alzheimer Disease* / metabolism
  • Clathrin / metabolism
  • Genetic Loci
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Monomeric Clathrin Assembly Proteins* / genetics
  • Monomeric Clathrin Assembly Proteins* / metabolism

Substances

  • Clathrin
  • Monomeric Clathrin Assembly Proteins
  • PICALM protein, human

Grants and funding

This study was supported by grants from the Belgian Fonds de la Recherche Scientifique Médicale to J.-P.B. (2019/0027), the Fund Aline (King Baudouin Foundation) to J.-P.B. (14001), the Foundation for Alzheimer Research (FRA/SAO) to K.L. (2021/0028) and the Génicot Fund of ULB to J.-P.B. and K.L.